-
-
SECOND GENERATION OF HIGHLY-EFFECTIVE ABSORBED TETANUS VACCINE OBTAINED THE CLINICAL TRIAL APPROVAL
2024-12-19The clinical trial approval for the Group’s second generation of highly-effectiveabsorbed tetanus vaccine has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.
-
-
SUSPENSION CULTURE INFLUENZA VACCINE (MDCK CELLS) WITH NEW TECHNOLOGICAL ROUTE OBTAINED THE CLINICAL TRIAL APPROVAL
2024-12-19The clinical trial approval for the Group’s suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine. Currently, all influenza vaccines available on the domestic market are produced using chicken embryo technology. There have not been cell-based influenza vaccines approved for marketing. As a heavyweight key product, influenza vaccine (MDCK cells) is expected to become a new growth driver of the Group after its launch.
-
-
Phase-1 clinical test for mRNA COVID-19 vaccine of AIM Vaccine is in smooth progress, manifesting a high safety and tolerance
2021-09-11 -
By September 9, AIM Vaccine had completed low-dosage and medium-dosage recruitment of adult patients for mRNA COVID-19 vaccine at phase-1 clinical laboratory of Shulan (Hangzhou) Hospital. According to results of preliminary test, the vaccine has manifested a high safety and tolerance after inoculation.
-
-
-
AIM Vaccine enlisted for important contracted project for “Two-zone” construction in Beijing with introduced investments
2021-09-04 -
On the morning of September 3, Zhou Ting, Board Chairman and CEO of AIM Vaccine Co., Ltd attended “One-day for Beijing” and anniversary celebration of “Two-zone” construction at 2021 China International Fair for Trade in Services under invitation, and participated in the signing ceremony for “Two-zone” project. PRC head office and phase-1 project innovative vaccine industrialization base of AIM Vaccine have been listed as important contracted projects for “two-zone” construction in Beijing with introduced investments through strict screening. It is one of 37 key projects completed contract conclusion with Beijing Economic-Technological Development Area t the site on the current day.
-
-
-
AIM COVID-19 vaccine achieved critical progress in industrialization
2021-07-21 -
Ningbo Rong’an Biological Pharmaceutical Co., Ltd, the wholly owned subsidiary of AIM Vaccine has recently obtained Approval Form of Clinical Trial as approved and issued by National Medical Products Administration.
-
-
-
AIM Vaccine completed acquisition of Lifanda to accelerate deployment of mRNA COVID-19 Vaccine
2021-06-01 -
On May 31, AIM Vaccine Co., Ltd completed acquisition of Zhuhai Lifanda Biology Co., Ltd, holding 50.1546% of its shares. Lifanda Biology is one of 3 enterprises obtained clinical approval of mRNA COVID-19 vaccine.
-
